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At least eight intronic p53 polymorphisms have been detected in
human genomic p53. These include a VNTR (variable number
tandem repeat) region (Hahn et al, 1993) and a HaeIII restriction
fragment length polymorphism (RELP) (Ito et al, 1994) in intron
1, a G-to-C transversion in intron 2 (38 bp downstream of exon 2)
(Pleasants and Hansen, 1994), a 16 bp duplication in intron 3
(5¢-gacctggagggctggg-3¢) (Lazar et al, 1993), a MspI RFLP in
intron 6 (G-to-A transition at 61 bp downstream of exon 6) (Peller
et al, 1995; Mavridou et al, 1998), a G-to-C transversion at 37 bp
upstream to exon 7 (Hillebrandt et al, 1997), an ApaI RFLP in
intron 7 (Prosser and Condie, 1991), and an A-to-T transversion in
intron 10 (Buller et al, 1995). Associations between cancer pheno-
types and inherited p53 intronic polymorphisms have been
observed in studies on epithelial cancers, including ovarian,
breast, colon, gastric, nasopharyngeal, thyroid, bladder and lung
cancer (Birgander et al, 1995, 1996; Peller et al, 1995; Runnebaum
et al, 1995; Sjalander et al, 1995, 1996; Hillebrandt et al, 1997;
Mavridou et al, 1998; Wang-Gohrke et al, 1998b). In a previously
reported clinic-based case-control study on the 16 bp duplication
polymorphism in intron 3 we have found the rare allele to be
significantly more frequent in ovarian cancer patients (n = 62) than
in healthy controls (Runnebaum et al, 1995), this observation was
not confirmed in two other studies on ovarian cancer patients
(Lancaster et al, 1995; Campbell et al, 1996). Common variants of
the p53 intron sequences may represent low-penetrance germline
mutations which affect p53 gene function. The objectives of this
study were to test whether germline p53 polymorphisms in intron
3 and 6 modified the risk of ovarian cancer.
MATERIALS AND METHODS
Case-control study on German ovarian cancer patients
and healthy controls
A total of 310 ovarian cancer patients selected without regard to
family history were identified who underwent surgery for histologi-
cally confirmed ovarian cancer at the University of Ulm from 1980 to
1995 and at the University of Mainz from 1980 to 1994. The age of
the women ranged from 15 to 91 years with a mean age of 59 years.
Blood samples were collected from 364 German female blood
donors at the University of Ulm in 1993 to serve as controls. Blood
donors had a history of no cancer and were unselected with respect to
family history of cancer. Donors participated on a voluntary basis
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79106 Freiburg, Germany.without financial incentives. All cases and controls were white
German women from Southern and Central Germany. The average
age of the controls was 41 years ranging from 17 to 65. Statistical
adjustment for age was done as described below.
BRCA1 and BRCA2 mutation carriers
A total of 400 carriers of deleterious BRCA1 or BRCA2 mutations
were studied. The carriers originated from 212 breast-ovarian
families in North America who were collected in the course of
several epidemiological studies. There were 325 carriers of
BRCA1 mutations and 75 carriers of BRCA2 mutations. One
hundred and twenty-four of the 400 carriers had a history of
ovarian cancer and 276 had no history of ovarian cancer. One
hundred and twenty-seven of the carriers were Ashkenazi Jewish,
including 79 of the women with ovarian cancer. The average age at
the time of diagnosis of the ovarian cancer cases was 54.8 years
compared to 47.6 years for the carriers without ovarian cancer.
Both, affected and unaffected carriers came from the same
families and so the ethnic distribution of the groups was similar.
Ovarian cancer cell lines
Twenty-nine human ovarian cancer cell lines were established
from primary ovarian cancer tissue as described previously
(Mobus et al, 1992). The cells were grown in Dulbecco￿s modified
Eagles medium (DMEM) containing 10% fetal calf serum, 
200 mM glutamine, and 100 mg ml—1 penicillin and 100 mg ml—1
streptomycin in 5% carbon dioxide at 37°C and harvested at about
70% confluence.
DNA extraction
Genomic DNA of cell lines and EDTA blood samples was
extracted by the phenol chloroform method. For 158 cases,
genomic DNA was isolated from the formalin-fixed paraffin-
embedded uterine tissue unaffected by ovarian cancer by the
sodium acetate precipitation method. Genomic DNA extraction
for BRCA1 or BRCA2 carriers has been described elsewhere
(Phelan et al, 1996).
Genotyping
The analysis of the p53 polymorphic sites was based on the poly-
merase chain reaction (PCR) amplification of two fragments
encompassing the 16 bp duplication polymorphism in intron 3 and
the MspI RFLP in intron 6 (Wang-Gohrke et al, 1998b). All PCRs
were carried out with 30 cycles each consisting of 1 min de-
naturing at 94°C, 1 min of annealing (60°C for intron 3, 54°C for
intron 6) and 1 min of extension at 72°C. The amplification of the
16 bp duplication polymorphism using the sense primer OL-297
(5¢-CTG AAA ACA ACG TTC TGG TA-3¢) and antisense primer
OL-298 (5¢-AAG GGG GAC TGT AGA TGG GTG-3¢) resulted
in a 119 bp or 135 bp fragment. The 16 bp A1 allele was defined
as the absence of the duplication, according to previous publica-
tions (Lazar et al, 1993; Runnebaum et al, 1995). The MspI RFLP
sense primer OL-301 (5¢-TGG ATG ACA GAA ACA CTT TTC
G-3¢) and the antisense primer OL-302 (5¢-GTG GTA CAG TCA
GAG CCA ACC-3¢) resulted in either a 152 bp fragment which
after MspI digest produced a 100 bp and a 52 bp fragment or in a
152 bp fragment which contained no MspI cutting site. The PCR
products were directly or following restriction enzyme digest run
on a high resolution Hydrolink gel (AT Biochem, Malvern, USA)
and processed by the software Fragment Manager in the auto-
mated sequencer ALF Express (Pharmacia Uppsala, Sweden). All
individuals with a genotype containing the rare alleles hetero-
zygously or homozygously were reanalysed starting from the
DNA sample.
Genomic DNA and cDNA sequencing of the p53 gene
Genomic DNA of all 29 ovarian cancer cell lines was sequenced
from exon 4 to exon 9 according to an established protocol (Wang-
Gohrke et al, 1998a). For cDNA sequencing, total RNA was
isolated from the cells by TRlzol¤ Reagent (GibcoBRL, Life
Technologies, Inc, New York, USA). The first strand cDNA was
synthesized by the RNAase H— Reverse Transcriptase directed by
Oligo(dT)12—18 Primer (GibcoBRL). Three primer pairs were
designed to amplify three overlapping fragments which covered
the entire cDNA sequence of p53. M13 forward and reverse
primer sequences were attached to the 5¢ terminus of the sense or
antisense primer which allowed the sequencing of the PCR-frag-
ments using M13 forward or reverse primers. The sequences of the
three primer pairs were the following: p53cDNA1s: 5¢-CCG GGG
ACA CTT TGC GTT CG-3¢, p53cDNA1as: 5¢-TGA TTC CAC
ACC CCC GCC C-3¢; p53cDNA2s: 5¢-ACT CCC CTG CCC TCA
ACA AGA TG-3¢, p53cDNA2as: 5¢-AGC ACT AAG CGA GCA
CTG CCC A-3¢; p53cDNA3s: 5¢-ACC GGC GCA CAG AGG
AAG AGA A-3¢, p53cDNA3as: 5¢-CAT TTG CTT TGT CCC
GGG GCT-3¢. Annealing temperature for fragment 1 and 2 was
62°C and 64°C for fragment 3. PCR and cycle sequencing reac-
tions have been described previously (Wang-Gohrke et al, 1998a).
Cy5¢-labelled (Cyanide) M13 forward and reverse primers were
used in cycle sequencing. The products were analysed on a 6%
denaturing acrylamide sequencing gel on an ALF Express
Sequencer (Pharmacia Biotech, Uppsala, Sweden).
Statistics
The association between 16 bp duplication polymorphism or MspI
RFLP and ovarian cancer was first estimated by comparing the
proportions of women affected and unaffected by ovarian cancer,
who carried the 16 bp A2 or the MspI A1 allele. Statistical signifi-
cance of the different proportions was measured by c2 test. Yate￿s
correction was used to identify deviations from Hardy—Weinberg
proportions among cases and controls. Logistic regression models
and stratified analysis for the case-control analysis controlling for
age were used to estimate odds ratios (OR) and 95% confidence
intervals (CI). Differences in genotypes as well as allele frequen-
cies are given as D-values. The odds ratio for ovarian cancer in
BRCA1 or BRCA2 carriers with or without the rare allele of p53
polymorphisms was estimated using a Mantel—Haenszel approach.
Significant associations were identified at the P < 0.05 level. All
computations were performed using SAS, release 6.12 (SAS
Institute, Carey, NC, USA).
RESULTS
Genotype analysis in German ovarian cancer patients
and controls
Genotype analysis was performed for two polymorphic sites in the
p53 gene of 310 German women with ovarian cancer and 364
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allele) was found to be significantly associated with ovarian cancer
(P= 0.001, Table 1) in German women with an increased odds
ratio (OR adjusted for age 1.93, 95% CI 1.27—2.91). When
analysing cases and controls by age groups, the odds ratios for
MspI A1 allele were found significantly high only in the patients
with an age at diagnosis of 41—60 (OR 2.71, CI 1.10—6.71 for
41—50 and OR 2.44, CI 1.12—5.28 for 51—60). The 16bp duplica-
tion polymorphism was found to be in a strong linkage to the MspI
RFLP. This linkage was observed in 287/310 (92.6%) ovarian
cancer cases and in 355/364 (97.5%) controls. The age-adjusted
odds ratio for the intron 3 16bp rare allele (A2 allele) was 1.71,
95% CI 1.17—2.49 (P= 0.003). For 16bp duplication polymor-
phism, the OR was significantly high only in the patients with an
age at diagnosis of 51—60 (OR 2.2, CI 1.03—4.7). The genotype
distributions in patients and controls did not deviate from expected
Hardy—Weinberg frequencies at either site (Table 1).
At both polymorphic sites, the heterozygotes were more
frequent in the ovarian cancer patients than the controls (for MspI
A1A2, D= 10%; for 16bp A1A2, D= 8%). Among the ovarian
cancer cases, the genotypes which were homozygous for the
common allele (for MspI A2A2, D= 11%; for 16bp A1A1,
D= 10%) were less frequent (Table 1). For both polymorphisms,
the number of carriers of the rare allele was significantly higher in
ovarian cancer patients (P= 0.004 for 16bp duplication, P= 0.001
for MspI RFLP).
For each individual, combined genotypes of both polymor-
phisms were analysed. A significant difference was found between
patients and controls when the combination of common homo-
zygotes (16bp A1A1-MspI A2A2) was compared with either the
remaining genotypes (P= 0.001, Table 2) or the double hetero-
zygotes (P= 0.005). Overall, double heterozygotes of the two
polymorphisms were significantly more frequent in the ovarian
cancer patients (26.5%) than in the control group (20.1%) with an
age-adjusted OR of 1.65 (95% CI 1.07—1.11). This increased odds
ratio was found to be significant only in the patients with an age at
diagnosis of 51—60 (OR 2.3, CI 1.05—5.06). The common homozy-
gote combination 16bp A1A1-MspI A2A2 was found with a
higher frequency in the control group (D= 12.4%) resulting in a
decreased age-adjusted OR of 0.52 (95% CI 0.35—0.77).
Genotype analysis of BRCA1 or BRCA2 mutation
carriers
Overall, the 16bp A2 allele was seen in 25.8% of the carriers. The
frequency was not significantly different for Jewish carriers
(29.1%) and for non-Jewish carriers (24.2%). The frequency of the
p5316bp duplication variant was not higher in the carriers with
ovarian cancer (26.6%) than in carriers without ovarian cancer
(25.4%). The odds ratio for ovarian cancer among those with the
16bp A2 allele was 1.07 (95% CI 0.66—1.37). This odds ratio was
higher for BRCA1 carriers (OR = 1.24) than for BRCA2 carriers
(OR = 0.70) but neither of these ORs were statistically significant.
Furthermore, there was no difference between the age of onset of
ovarian cancer in the carriers with and without the 16bp duplica-
tion; the average age at diagnosis of ovarian cancer for the 33
cases with the A2 allele was 55.0 years and the average age for the
91 cases without the A2 allele was 54.7 years. In the BRCA1 or
BRCA2 carriers, the 16bp duplication polymorphism in intron 3
was also found to be in a strong linkage to the MspI RFLP in intron
6. Overall, there was no association between p53polymorphism
status and the presence of ovarian cancer in individuals with
germline mutations in BRCA1 or BRCA2.
Ovarian cancer cell lines
Twenty-nine cell lines were typed for both polymorphisms. The
rare allele of the MspI RFLP was in linkage with the rare allele of
the 16bp duplication polymorphism except for one cell line. For
both polymorphisms, 25 cell lines were identified as homozygous
for the common alleles (16bp A1A1-MspI A2A2), two as
homozygous for the rare alleles (16bp A1A1-MspI A2A2) and
one cell line was heterozygous. One other cell line showed a
heterozygous 16bp duplication polymorphism and a homozygous
common allele of MspI RFLP (OV-MZ-33). No splicing error was
found when the p53sequencing was applied to the entire cDNA.
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Table 1 p53 genotypes and allele frequencies in ovarian cancer patients and healthy controls
Polymorphism Group n p53 Genotype Allele Freq. c2HW ORe 95% CI
1–1 1–2 2–2 A1 A2
16bp Controls 364 297 82 3 0.88 0.12 0.85
Casesc 310 207 95 8 0.82 0.18a 0.34 1.71 1.17–2.49
MspI RFLP Controls 364 3 73 288 0.11 0.89 0.20
Casesd 310 7 92 211 0.17b 0.83 0.42 1.93 1.27–2.91
Differences of allele frequencies: Chi-square test, df = 1; Cases vs Controls afor 16bp, p = 0.003; bfor MspI, P = 0.001. Differences of genotype distributions:
Chi-square test, df = 1; rare allele carriers vs common allele carriers: c16bp (A2A2 + A1A2) vs A1A1: P = 0.004; dMspI (A1A1 + A1A2) vs A2A2: P = 0.001.
c2HW: Chi-square values testing deviation from Hardy-Weinberg proportions (Yate’s correction; df = 1). eAge-adjusted odds ratio.
Table 2Genotype combinations of the p53 polymorphisms in ovarian
cancer cases and healthy controls
16bp MspI RFLP Cases Controls ORa 95% CI
1–1 2–2 199 279 0.52b 0.35–0.77
2–1 2–1 82 73 1.65c,d 1.07–1.11
1–1 2–1 8 0
2–2 1–1 6 3 2.18c 0.86–5.52
2–1 2–2 12 9 1.66c 0.59–4.63
2–2 2–1 2 0
2–1 1–1 1 0
Total 310 364
aAge-adjusted odds ratio. Cases vs Controls: 16bp A1A1-MspI A2A2, bvs the
remainder of the combinations, P = 0.001; dvs 16bp A1A2-MspI A1A2, P =
0.005 (Chi-square test, df = 1). cAll were compared with the combination of
16bp A1A1-MspI A2A2.No mutation was identified in the 5¢ or 3¢ splice sites by
genomic DNA sequencing of the flanking introns. In two cell lines
with the genotype of 16 bp A1A1-MspI A2A2, an A to G transi-
tion mutation at codon 205 of p53 changed the amino acid
sequence from a tyrosine to a cysteine in the OV-UL-02 cell line.
The other cell line OV-MZ-22 had a wild-type sequence in cDNA
and genomic DNA analysis.
DISCUSSION
This study shows that germline variants of intron sequences of the
p53 gene or linked genetic variations may play a role in the devel-
opment of sporadic ovarian cancer. The rare allele of MspI RFLP
was found to be associated with a more than twofold increase of
risk in an age-dependent manner (OR 2.71, 95% CI 1.10—6.71 for
41—50 and OR 2.44, 95% CI 1.12—5.28 for 51—60). In an initial
study on different cancer types, an increased number of MspI
RFLP heterozygotes were found in the germline DNA of gastro-
intestinal (GI) tumour patients (47.6%, n = 21, P = 0.17) and
breast cancer patients (50%, n = 20, P = 0.12) comparing with a
healthy control group (31.6%, n = 38) (Peller et al, 1995). A
significant association was reported from a case-control study (65
vs 117) on American Caucasian breast cancer patients (Weston et
al, 1997). The allele frequency of the rare MspI RFLP was higher
in cases (0.21) than in controls of the same ethnic background
(0.11, P = 0.02). However, such an association was observed
neither in our German (0.11 vs 0.15, P = 0.075) nor in an English
case-control study (0.09 vs 0.10, P = 0.88) (Mavridou et al, 1998;
Wang-Gohrke et al, 1998b). The comparison of the different
studies is legitimate since the frequencies of the rare MspI allele
were similar in the Caucasian healthy control individuals in the
American (0.11, n = 117), the English (0.10, n = 254) and German
(0.11, n = 305) studies. It is possible that the significant associa-
tion in the American Caucasian case-control study might be due to
the specific ethnicity, the environment or the smaller size of the
cohort genotyped (Weston et al, 1997). Another study on the same
polymorphism in a Swedish population with and without breast
cancer (212 vs 689) (Sjalander et al, 1996) could not be directly
compared with other studies since the majority of the controls in
this Swedish study consisted of placental samples. Another study
which did not provide information on age found an association of
this polymorphism with ovarian cancer (0.16 vs 0.10, P = 0.01)
(Mavridou et al, 1998). In our study, this polymorphism did not
appear to play a role in ovarian cancer development below the age
of 40 (early-onset ovarian cancer).
We found the rare allele of the MspI RFLP in a strong linkage
with the rare allele of the 16 bp duplication polymorphism in
controls (97.5%) as well as in ovarian cancer cases (92.6%).
Therefore, it was not surprising to find that the genotype distribu-
tion of the 16 bp duplication polymorphism and its overall esti-
mated relative risk for ovarian cancer (OR adjusted for age 1.71,
95% CI 1.17—2.49) were similar to those of the Msp I RFLP. In a
previous pilot study, we have reported that the rare allele of the
16 bp duplication polymorphism intron 3 was significantly more
frequent in a small group of German ovarian cancer patients (0.27,
n = 62, P = 0.001) than in healthy controls (0.14, n = 424)
(Runnebaum et al, 1995). This difference was observed neither in
a British (0.16 vs 0.15) nor in an American (0.09 vs 0.13) case-
control study (216 vs 113 and 82 vs 100 respectively) on
Caucasian ovarian cancer patients (Lancaster et al, 1995;
Campbell et al, 1996). Our current study confirms the higher
prevalence of the rare allele in the cases as previously reported,
even though the high frequency of homozygotes of the rare allele
in our previous group was not representative (Runnebaum et al,
1995). Factors such as age, ethnicity and environment may have
contributed to results differing from ours. No information on age
was provided by the British and the American group.
Hereditary ovarian cancer can occur in the familial breast-
ovarian cancer syndrome or in the hereditary non-polyposis
colorectal cancer (HNPCC) syndrome which can include cancers
of the colon, endometrium, breast or urinary tract (Lynch et al,
1991, 1993). The majority (81%) of the breast-ovarian cancer
families are due to BRCA1, with most others (14%) due to BRCA2
(Ford et al, 1998). By the age of 70, the recently estimated risk of
breast cancer among BRCA1 and BRCA2 carriers was 56% and of
ovarian cancer 16% (Struewing et al, 1997). It has been hypothe-
sized that the penetrance of BRCA1 or BRCA2 mutations could be
modified by genetic and non-genetic factors. HRAS1 variable
number of tandem repeat (VNTR) locus was identified to have an
effect as a modifying gene variant on the penetrance of BRCA1
mutations for ovarian cancer (Phelan et al, 1996). In our case-
control study of ovarian cancer among 400 women who have been
identified to be carriers of a deleterious mutation in either the
BRCA1 or the BRCA2 gene, the allelic frequencies of the two
intronic p53 polymorphisms did not significantly differ. No effect
was found for the age of onset when comparing the carriers with
and without the rare allele of the p53 polymorphisms. This
suggests that the intronic polymorphisms of the p53 gene did not
modify the risk to develop ovarian cancer beyond the effect of
BRCA1 or BRCA2 mutations. The risk modification of p53 poly-
morphisms appeared to be limited to sporadic cases.
p53 introns have been shown to be implicated in regulation of
gene expression and DNA—protein interaction (Hinds et al, 1990;
Beenken et al, 1991; Lozano and Levine, 1991; Shamsher and
Montano, 1996; Avigad et al, 1997). Single base pair substitutions
in intron 4 have been shown to disturb binding of unidentified
proteins resulting in a decreased expression of p53 (Beenken et al,
1991). Avigad et al (1997) identified a germ line variant in intron 6
(G-to-A substitution at 39 bp upstream of exon 7) in six paediatric
patients with diverse tumours, all of which belonged to the
Li—Fraumeni syndrome. High p53 protein expression was
observed by immunohistochemistry (anti-p53 antibody DO-1) in
the two available tumours and in one normal lymph node which
carried a wild-type p53 sequence in the coding region. The authors
concluded that this intron mutation either caused or was linked
with a variation leading to stabilization and possible inactivation of
the p53 protein thereby contributing to neoplastic transformation
(Avigad et al, 1997). In our study, a medium or low p53 expression
was observed in three wild-type p53 cell lines with the rare allele
of both p53 intronic polymorphisms. The immunostaining did not
differ from the ICC pattern of 13 other cell lines with wild-type
p53 without the rare allele. As analysed by sequencing of genomic
DNA and cDNA, mutations in the coding region are not neces-
sarily linked to the polymorphisms. As demonstrated by the cell
line with a p53 mis-sense mutation, the two polymorphisms did not
seem to be sufficient to impair p53 function during the selection
process in tumorigenesis but needed an additional coding region
mutation. No splicing errors were found to be linked to the poly-
morphisms. The data presented here encourage to further study the
possible mechanisms by which the germline intron 3 and intron 6
variants modify cancer risk and to search for closely linked genetic
aberrations in neighbouring genes.
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